Osimertinib-induced rapid regression of large metastatic tumor to the pituitary in a patient with lung adenocarcinoma

Surgical Neurology International - Tập 12 - Trang 13
Andrew K. Wong1, Troy W. Close2,3,4, Ricky H. Wong5
1Department of Neurosurgery, Rush University Medical Center, Chicago, Departments of 2 Ophthalmology,
2Clinical Professor of Neurological Surgery, School of Medicine, State U. of NY at Stony Brook.
3Department of Ophthalmology, North Shore University Health System, Evanston, Illinois, United States.
4Kanazawa University, Ishikawa, Japan
5Department of Neurosurgery, North Shore University Health System, Evanston, Illinois, United States.

Tóm tắt

Background: Metastatic nonsmall cell lung cancer (NSCLC) to the pituitary (NSCLC-PitM) is rare and often presents with visual field deficits. Surgical resection for the decompression of the optic apparatus has been the treatment of choice in such cases. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) approved for the treatment of patients with NSCLC with an epithelial growth factor receptor (EGFR) mutation though its role in the treatment of NSCLC-PitM that remains unclear. We present a case of NSCLC-PitM with optic chiasm compression and visual deficits that were successfully treated with osimertinib alone without surgical intervention. Case Description: A 43-year-old male presented with pleuritic chest pain, fatigue, and visual deficits found to have NSCLC and a sellar mass with suprasellar extension and optic chiasm compression. Visual field testing demonstrated associated visual field deficits. Molecular testing was positive for EGFR exon 19 deletion. The patient was started on osimertinib with complete resolution of pituitary lesion and visual deficits at 4 weeks. Conclusion: Osimertinib is a third-generation EGFR-TKI that has demonstrated promising results among patients with metastatic EGFR-mutated NSCLC. While surgery is the mainstay of treatment in patients with a sellar mass, optic compression, and visual deficits, those with EGFR-mutated NSCLC-PitM may benefit from early initiation of such systemic therapies, rather than surgical intervention, with good ophthalmologic results.

Từ khóa


Tài liệu tham khảo

Adashek, 2018, EGFR T790M-positive lung adenocarcinoma metastases to the pituitary gland causing adrenal insufficiency: A case report, Case Rep Oncol Med, 2018, 2349021

Ayeni, 2015, Emerging agents and new mutations in EGFR-mutant lung cancer, Clin Cancer Res, 21, 3818, 10.1158/1078-0432.CCR-15-1211

Ballard, 2016, Preclinical comparison of osimertinib with other EGFRTKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity, Clin Cancer Res, 22, 5130, 10.1158/1078-0432.CCR-16-0399

Fan, 2019, Complete resolution of sellar metastasis in a patient With NSCLC treated with osimertinib, J Endocr Soc, 3, 1887, 10.1210/js.2019-00217

Javanbakht, 2018, Pituitary metastasis: A rare condition, Endocr Connect, 7, 1049, 10.1530/EC-18-0338

Megyesi, 2019, P14.111 Successful treatment of extensive metastatic disease with successive use of two different EGF receptor antagonists: Case report and review of the literature, Neuro Oncol, 21, iii94, 10.1093/neuonc/noz126.346

Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, New Engl J Med, 376, 629, 10.1056/NEJMoa1612674

Okauchi, 2018, Paradoxical response to osimertinib therapy in a patient with T790M-mutated lung adenocarcinoma, Mol Clin Oncol, 8, 175

Rahmathulla, 2012, The molecular biology of brain metastasis, J Oncol, 2012, 723541, 10.1155/2012/723541

Shan, 2019, CMET-10, Intracranial solitary pituitary metastasis: The implications from five cases, Neuro Oncol, 21, vi53, 10.1093/neuonc/noz175.211

Soria, 2018, Osimertinib in untreated EGFR-mutated advanced nonsmall-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137

Thông tin
Thông tin xuất bản

Surgical Neurology International

Tập 12

13

Thông tin tác giả